Circadian Therapeutics Announce the Appointment of Dr. Mark Sampson
Circadian Therapeutics Ltd is delighted to announce the appointment of Dr Mark Sampson as Chief Executive Officer and Board Member of the Company, effective 1st July 2020.
Most recently Chief Medical Officer of Shield Therapeutics PLC, Dr Sampson has had a distinguished, 30-year career as a pharmaceutical physician in both Clinical Development and Medical Affairs roles across pharmaceutical, biotech and consumer products companies. He has held leadership roles in medical affairs for firms including Shionogi, Viropharma, Gilead, Amgen and SmithKline Beecham. Dr Sampson began his medical career in the NHS across a range of clinical specialities and holds an MBChB from the University of Glasgow. He was a member of the Prescription Medicines Code of Practice Appeals board for over 10 years.
Commenting on the appointment, Chairman Dr Mike Snape said: “Mark joins us with a great track record and the right qualifications at the right time: The company is currently accelerating its R&D on our pipeline of promising circadian rhythm regulation candidates and Mark’s experience of the Central Nervous System field, and Phase I and Phase II trials, will be invaluable in driving our near-term progress. This is an exciting time for a ground-breaking company.”
Dr Sampson commented: “I am delighted and honoured to be joining an incredible team at Circadian Therapeutics at an exciting time for the company. Circadian rhythms play a central role in human physiology and disruption can significantly impact health. I look forward to working with the team to bring solutions to improve lives”